Dr. Andrin Oswald is the director of Life Sciences Partnerships, overseeing the foundation’s engagements with corporations.
Prior to joining the foundation, he was CEO and division head of Novartis Vaccines and Diagnostics from 2008 until its acquisition by GSK in 2015. He was a member of the executive committee of Novartis. In September 2013, Andrin also became chairman of the board of the Novartis Foundation for Sustainable Development. Prior to that he served as CEO of Speedel holding AG and global head of Pharmaceutical Development Franchises in the Novartis Pharmaceuticals Division, both in Switzerland. Andrin joined Novartis in 2005 as assistant to the chairman and CEO. Before his appointment as head of Development Franchises, he served as head of the Country Pharmaceuticals Organization (CPO) and country president for Novartis in South Korea. He joined Novartis from McKinsey & Company, Switzerland, where he was an associate principal.
Andrin is a board member of the Global Health Investment Corporation (GHIC), and an Investment Committee member of the Global Health Investment Fund (GHIF). From 2012 to 2013 he was a member of the Global Agenda Council on Catastrophic Risks of the World Economic Forum. Between 2002 and 2003, he also served as a delegate of the International Committee of the Red Cross (ICRC) in Nepal. Andrin holds a doctorate in medicine from the University of Geneva.